資源描述：
《Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫(kù)。
1、Yuetal.BMCMedicine(2015)13:254DOI10.1186/s12916-015-0496-zSpotlightonbreastcancerRESEARCHARTICLEOpenAccessMolecularessenceandendocrineresponsivenessofestrogenreceptor-negative,progesteronereceptor-positive,andHER2-negativebreastcancer**Ke-DaYu,Yi-ZhouJiang,Shuang
2、HaoandZhi-MingShaoAbstractBackground:Theclinicalsignificanceofprogesteronereceptor(PgR)expressioninestrogenreceptor-negative(ER–)breastcanceriscontroversial.Herein,wesystemicallyinvestigatetheclinicopathologicfeatures,molecularessence,andendocrineresponsivenessof
3、ER?/PgR+/HER2?phenotype.Methods:Fourstudycohortswereincluded.ThefirstandsecondcohortswerefromtheSurveillance,Epidemiology,andEndResultsdatabase(n=67,932)andFudanUniversityShanghaiCancerCenter(n=2,338),respectively,forclinicopathologicandsurvivalanalysis.Thethirda
4、ndfourthcohortswerefromtwoindependentpubliclyavailablemicroarraydatasetsincluding837operablecasesand483casesundergoingneoadjuvantchemotherapy,respectively,forclinicopathologicandgene-expressionanalysis.CharacterizedgenesdefiningsubgroupswithintheER–/PgR+/HER2–phe
5、notypeweredeterminedandfurthervalidated.Results:ClinicopathologicfeaturesandsurvivaloutcomesoftheER–/PgR+phenotypefellinbetweentheER+/PgR+andER?/PgR?phenotypes,butweremoresimilartoER?/PgR?.AmongtheER?/PgR+phenotype,30%(95%confidenceinterval[CI]17–42%,pooledbyafix
6、ed-effectsmethod)wereluminal-likeand59%(95%CI45–72%,pooledbyafixed-effectsmethod)werebasal-like.WefurtherrefinedthecharacterizedgenesforsubtypeswithintheER?/PgR+phenotypeanddevelopedanimmunohistochemistry-basedmethodthatcoulddeterminethemolecularessenceofER?/PgR+
7、usingthreemarkers,TFF1,CK5,andEGFR.EitherPAM50-definedorimmunohistochemistry-definedbasal-likeER?/PgR+caseshavealowerendocrinetherapysensitivityscorecomparedwithluminal-likeER?/PgR+cases(P<0.0001byMann-WhitneytestforeachstudysetandP<0.0001forpooledstandardizedmea
8、ndifferenceinmeta-analysis).Immunohistochemistry-definedbasal-likeER?/PgR+casesmightnotbenefitfromadjuvantendocrinetherapy(log-rankP=0.61forsufficientversusins
